299 related articles for article (PubMed ID: 15860163)
1. [Drugs in the European Union: the health-market complex].
Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
[TBL] [Abstract][Full Text] [Related]
2. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity].
Puig-Junoy J
Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178
[No Abstract] [Full Text] [Related]
3. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
Vogel RJ
Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
5. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
Pashkov V; Soloviov A; Olefir A
Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical regulation in the European Community: barriers to single market integration.
Orzack LH; Kaitin KI; Lasagna L
J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
[TBL] [Abstract][Full Text] [Related]
7. Medicinal products in the European Union--between harmonization and divergence.
Lojko N
Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
[TBL] [Abstract][Full Text] [Related]
8. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the pharmaceutical market in Poland after accession to the European Union.
Willert PL
Eur J Health Econ; 2007 Dec; 8(4):347-57. PubMed ID: 17186200
[TBL] [Abstract][Full Text] [Related]
10. The market for pharmaceuticals.
Bergenheim K; Braun U
Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
[No Abstract] [Full Text] [Related]
11. Restrictions on import of drugs for personal use within the European single market.
Mäkinen MM; Rautava PT; Forsström JJ
Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
[TBL] [Abstract][Full Text] [Related]
12. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
13. Global Generic Medicines--Health Network Communications' Second Annual Summit.
Burck B
IDrugs; 2008 May; 11(5):328-30. PubMed ID: 18465671
[No Abstract] [Full Text] [Related]
14. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
15. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
16. Causes of drug shortages in the legal pharmaceutical framework.
De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
[TBL] [Abstract][Full Text] [Related]
17. Has the European union achieved a single pharmaceutical market?
Timur A; Picone G; DeSimone J
Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
[TBL] [Abstract][Full Text] [Related]
18. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
Ganslandt M; Maskus KE
J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
[TBL] [Abstract][Full Text] [Related]
19. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
Nettesheim M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
Glynn D
Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
